12/26/2025

Janusmed kön och genus

Janusmed kön och genus – Piperacillin

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Piperacillin

Piperacillin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Heikkilä A, Erkkola R. Pharmacokinetics of piperacillin during pregnancy. J Antimicrob Chemother. 1991;28:419-23.

  2. Voigt R, Schröder S, Peiker G. Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. Chemotherapy. 1985;31:417-24.

  3. Charles D, Larsen B. Pharmacokinetics of piperacillin in the postpartum patient. Gynecol Obstet Invest. 1985;20:194-8.

  4. Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int. 2010;52:262-7.

  5. Lee DS, Choe HS, Kim HY, Yoo JM, Bae WJ, Cho YH et al. Role of age and sex in determining antibiotic resistance in febrile urinary tract infections. Int J Infect Dis. 2016;51:89-96.

  6. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013. Clin Microbiol Infect. 2015;21(6):569e1-7.

  7. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.

  8. Gu J, Chen X, Yang Z, Bai Y, Zhang X. Gender differences in the microbial spectrum and antibiotic sensitivity of uropathogens isolated from patients with urinary stones. J Clin Lab Anal. 2022;36(1):e24155.

  9. Lemieux P, Grégoire JP, Thibeault R, Bergeron L. Higher risk of neutropenia associated with piperacillin-tazobactam compared with ticarcillin-clavulanate in children. Clin Infect Dis. 2015;60:203-7.

  10. Kim T, Kandiah S, Patel M, Rab S, Wong J, Xue W et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res Notes. 2015;8:579.

  1. Heikkilä A, Erkkola R. Pharmacokinetics of piperacillin during pregnancy. J Antimicrob Chemother. 1991;28:419-23.
  2. Voigt R, Schröder S, Peiker G. Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. Chemotherapy. 1985;31:417-24.
  3. Charles D, Larsen B. Pharmacokinetics of piperacillin in the postpartum patient. Gynecol Obstet Invest. 1985;20:194-8.
  4. Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int. 2010;52:262-7.
  5. Lee DS, Choe HS, Kim HY, Yoo JM, Bae WJ, Cho YH et al. Role of age and sex in determining antibiotic resistance in febrile urinary tract infections. Int J Infect Dis. 2016;51:89-96.
  6. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013. Clin Microbiol Infect. 2015;21(6):569e1-7.
  7. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.
  8. Gu J, Chen X, Yang Z, Bai Y, Zhang X. Gender differences in the microbial spectrum and antibiotic sensitivity of uropathogens isolated from patients with urinary stones. J Clin Lab Anal. 2022;36(1):e24155.
  9. Lemieux P, Grégoire JP, Thibeault R, Bergeron L. Higher risk of neutropenia associated with piperacillin-tazobactam compared with ticarcillin-clavulanate in children. Clin Infect Dis. 2015;60:203-7.
  10. Kim T, Kandiah S, Patel M, Rab S, Wong J, Xue W et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res Notes. 2015;8:579.